Servier adds mAb platform via takeout of former European biotech darling Symphogen

What was once a high-profile European biotech is now going out quietly as Servier is acquiring Danish mAb company Symphogen A/S for an undisclosed sum.

The two companies are partnered across three clinical stage immuno-oncology programs, a deal the French specialty pharma inherited when it bought the oncology business of Shire plc in 2018 for $2.4 billion (see “Servier to Gain Shire’s Cancer Business”)...